Longboard Pharmaceuticals (LBPH) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and asset highlights

• Spun out in 2020 to advance neurological assets with greater selectivity and specificity.

• Focused on bexicaserin and LP659, with LP659 targeting neurological conditions and moving into phase I MAD early next year.

• Bexicaserin is the primary focus due to significant investor interest and recent R&D event.

Commercial landscape and market opportunity

• Epidiolex, approved for three DEEs, is a billion-dollar drug six years post-launch, with significant pricing headroom compared to Fintepla.

• Potential for a multi-billion-dollar product by leveraging pricing, breakthrough designation, and global market expansion.

• Composition of matter patent extends to 2041, supporting long-term commercial potential.

Clinical development and trial design

• Phase III trial design aims to minimize variability from phase II PACIFIC study and maximize probability of success.

• TID dosing is commercially viable, with a direct path to BID approval for optimal market launch.

• Inclusion/exclusion criteria and endpoint selection are structured to reduce variability and enhance success probability.